Collgard is dedicated to developing products for the treatment of
the following diseases: cancer, restenosis, fibrosis and
autoimmune diseases.
Employees: 14
Overview
Founded in 1996, COLLGARD BIOPHARMACEUTICALS is a clinical stage
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
tissue therapeutics company, led by a global team of medical and
drug development experts from Boston to Atlanta and o Tel Aviv.
COLLGARD's tissue therapeutics product and platform technology is
based on Tempostatin (Halofuginone hydrobromide). Tempostatin, a
fully synthetic small molecule, is a potent and selective
regulator of stromal cell activation, cell migration and Collagen
type I synthesis, a process that COLLGARD has identified as a
"master switch" in the body's tissue repair process.
The company is currently engaged in phase II clinical studies
evaluating a novel approach to the prevention and treatment of
organ failure, restenosis and specific cancers.
